Skip to main content
Stephen Hansen on Muck Rack

Stephen Hansen

Verified
England, Peterborough
As seen in: BioCentury, The Washington Post, Harvard Business Review, Justia Dockets & Filings, JD Supra, VoxEU.org, Zephyrnet
Husband. Father of 2 exhausting boys. Director of Biopharma Intelligence @BioCentury. Lives → U.K., roots in Minnesota. Opinions my own. Landscape photography⬇⬇
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stephen

Contact Stephen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Perspective — siRNAs are better than ASOs

|
By Stephen Hansen Verified
| BioCentury Verified
ARTICLE | Editor's Commentary Why it might be time to just admit that siRNAs are the better modality By Stephen Hansen, Director of Biopharma Intelligence I think we may have reached the point at which we can just say that siRNAs are better therapeutic molecules than antisense oligonucleotides.
Open in Who Shared Issue with article?

Can M&A momentum carry biotech through year-end?

|
By Stephen Hansen Verified
| BioCentury Verified
ARTICLE | Finance M&A enthusiasm is carrying biotech amid tepid reception for launches. What happens if the AI trade goes bust? By Stephen Hansen, Director of Biopharma Intelligence A historic run of M&A drovebiotech’s outperformance in the first half of the year, with most investors expecting dealmaking to continue to support the sector through 3Q26. Heading into the summer months, biotech’s public markets are in a good place. Financings are being upsized and showing good postmarket performance.
Open in Who Shared Issue with article?

Parkinson’s deep dive & FDA trial reforms — a BioCentury podcast

|
By Stephen Hansen Verified
| BioCentury Verified
Plus AZ’s obesity build-out and FDA’s reversion to the mean on regulatory decisions By Stephen Hansen, Director of Biopharma Intelligence New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts review the most promising targets and trends shaping the Parkinson’s treatment landscape.
Open in Who Shared Issue with article?
See all 875 articles